Retrospective analysis of the financial break-even point for intrathecal morphine pump use in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The high cost of intrathecal morphine pump (ITMP) implantation may be the main obstacle to its use. Since July 2014, the Korean national health insurance (NHI) program began paying 50% of the ITMP implantation cost in select refractory chronic pain patients. The aims of this study were to investigate the financial break-even point and patients’ satisfaction in patients with ITMP treatment after the initiation of the NHI reimbursement. Methods: We collected data retrospectively or via direct phone calls to patients who underwent ITMP implan-tation at a single university-based tertiary hospital between July 2014 and May 2016. Pain severity, changes in the morphine equivalent daily dosage (MEDD), any adverse events, and patients’ satisfaction were deter-mined. We calculated the financial break-even point of ITMP implantation via investigating the patient’s actual medical costs and insurance information. Results: During the studied period, 23 patients received ITMP implantation, and 20 patients were included in our study. Scores on an 11-point numeric rating scale (NRS) for pain were significantly reduced compared to the baseline value (P ＜ 0.001). The MEDD before ITMP implantation was 0.59 [IQR: 0.55-0.82]. The total MEDD increased steadily to 0.77 [IQR: 0.53-1.08] at 1 year, which was 126% of the baseline (P ＜ 0.001). More than a half (60%) responded that the ITMP therapy was somewhat satisfying. The financial break-even point was 28 months for ITMP treatment after the NHI reimbursement policy. Conclusions: ITMP provided effective chronic pain management with improved satisfaction and reasonable financial break-even point of 28 months with 50% financial coverage by NHI program. (Korean J Pain 2017; 30: 272-80)
Abstract
Background: The high cost of intrathecal morphine pump (ITMP) implantation may be the main obstacle to its use. Since July 2014, the Korean national health insurance (NHI) program began paying 50% of the ITMP implantation cost in select refractory chronic pain patients. The aims of this study were to investigate the financial break-even point and patients’ satisfaction in patients with ITMP treatment after the initiation of the NHI reimbursement. Methods: We collected data retrospectively or via direct phone calls to patients who underwent ITMP implan-tation at a single university-based tertiary hospital between July 2014 and May 2016. Pain severity, changes in the morphine equivalent daily dosage (MEDD), any adverse events, and patients’ satisfaction were deter-mined. We calculated the financial break-even point of ITMP implantation via investigating the patient’s actual medical costs and insurance information. Results: During the studied period, 23 patients received ITMP implantation, and 20 patients were included in our study. Scores on an 11-point numeric rating scale (NRS) for pain were significantly reduced compared to the baseline value (P ＜ 0.001). The MEDD before ITMP implantation was 0.59 [IQR: 0.55-0.82]. The total MEDD increased steadily to 0.77 [IQR: 0.53-1.08] at 1 year, which was 126% of the baseline (P ＜ 0.001). More than a half (60%) responded that the ITMP therapy was somewhat satisfying. The financial break-even point was 28 months for ITMP treatment after the NHI reimbursement policy. Conclusions: ITMP provided effective chronic pain management with improved satisfaction and reasonable financial break-even point of 28 months with 50% financial coverage by NHI program. (Korean J Pain 2017; 30: 272-80)
참고문헌 (23)
- Cousins MJ, "Pain relief : a universal human right", Pain, 112, pp.1~4 (2004)
- Bolash R, "Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management : a retrospective analysis of 365 patients", Neuromodulation, 18, pp.150~155 (2015)
- Goldberg DS, "Pain as a global public health priority", BMC Public Health, 11, pp.770~ (2011)
- Breivik H, "The individual and societal burden of chronic pain in Europe : the case for strategic prioritisation and action to improve knowledge and availability of appropriate care", BMC Public Health, 13, pp.1229~ (2013)
- Breivik H, "Survey of chronic pain in Europe : prevalence, impact on daily life, and treatment", Eur J Pain, 10(4), pp.287~333 (2006)
- Smith BH, "Management of chronic pain in primary care", Curr Opin Support Palliat Care, 5, pp.137~142 (2011)
- Moore RA, "Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids", Arthritis Res Ther, 7, pp.1046~1051 (2005)
- Wallace M, "Long-term spinal analgesic delivery : a review of the preclinical and clinical literature", Reg Anesth Pain Med, 25, pp.117~157 (2000)
- Anderson VC, "A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain", Neurosurgery, 44, pp.289~300 (1999)
- Paice JA, "Clinical realities and economic considerations: efficacy of intrathecal pain therapy", J Pain Symptom Manage, 14, pp.S14~S26 (1997)
- Deer TR, "Practice choices and challenges in the current intrathecal therapy environment : an online survey", Pain Med, 10, pp.304~309 (2009)
- 김용철, "Intrathecal Morphine Infusion Therapy in Management of Chronic Pain: Present and Future Implementation in Korea", Yonsei Medical Journal, 57(2), pp.475~481 (2016), 연세대학교의과대학[DOI]
- The Korean Pain Society, "Textbook of pain medicine", pp.469~480 (2012), Shinwon Medical
- Tracey I, "How neuroimaging studies have challenged us to rethink: is chronic pain a disease?", J Pain, 10, pp.1113~1120 (2009)
- Hamza M, "Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain", Pain Med, 13, pp.1304~1313 (2012)
- Auld AW, "Intraspinal narcotic analgesia in the treatment of chronic pain", Spine(Phila Pa 1976), 10, pp.777~781 (1985)
- Turner JA, "Programmable intrathecal opioid delivery systems for chronic noncancer pain : a systematic review of effectiveness and complications", Clin J Pain, 23, pp.180~195 (2007)
- Duarte RV, "A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain", Pain Physician, 15, pp.363~369 (2012)
- Atli A, "Intrathecal opioid therapy for chronic nonmalignant pain : a retrospective cohort study with 3-year follow-up", Pain Med, 11, pp.1010~1016 (2010)
- Kumar K, "Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology : long-term benefits and efficacy", Surg Neurol, 55, pp.79~86 (2001)
- Grider JS, "Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain", Pain Physician, 14, pp.343~351 (2011)
- Konrad PE, "Intrathecal drug delivery systems(IDDS) : the implantable systems performance registry(ISPR)", Neuromodulation, 19, pp.848~856 (2016)
- Mueller-Schwefe G, "Cost effectiveness of intrathecal therapy for pain", Neuromodulation, 2, pp.77~87 (1999)